Hormone therapy alone for older women with early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a pill (a CDK4/6 inhibitor) used alone, without chemotherapy, is effective for older women with early-stage hormone-positive breast cancer. The goal is to reduce the risk of cancer returning while avoiding the side effects of chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years or older and have been assigned female at birth.
- You must have had surgery for early-stage breast cancer that is hormone receptor positive (ER+) and HER2 negative.
- Your tumor must have spread to at least 1 lymph node, and you must meet additional risk criteria.
- You must be willing to take a CDK4/6 inhibitor (a type of pill that helps stop cancer cells from growing).
- You must be reasonably healthy overall, with acceptable blood counts and organ function.
- You must not have had chemotherapy or other cancer treatments before your surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether women aged 65 and older with a certain type of early breast cancer can safely skip chemotherapy and instead receive a pill that helps stop cancer cells from growing. The goal is to reduce treatment side effects while keeping the cancer from coming back.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests whether adding a targeted therapy (a CDK4/6 inhibitor) to standard hormone therapy can let some people safely skip chemotherapy. It is for early-stage, hormone-positive breast cancer that is also HER2-positive, and aims to reduce side effects while keeping the cancer from coming back.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.